Atopic Dermatitis Agreement

« We see a high uninsed need for safe and effective oral treatments for people with atopic dermatitis. That`s why we`re collaborating with JW Pharmaceutical on its new drug candidate for oral atopic dermatitis, JW1601. At LEO Pharma, we are constantly striving to expand our pipeline with new innovative solutions, with the ultimate goal of providing the many patients we will care for with real, life-changing medicines. This connection aligns perfectly with our existing biologicians, currently in Phase III (tralokinumab) and Phase I (LP0145), and our topical delgocitinib, currently in Phase II, » said Kim Kjoeller, Executive Vice President, Global R&D, LEO Pharma. Leo Pharma has agreed to a more than $900 million ($900 million) deal to buy the global rights to AstraZenecas ($AZN), an atopic tralokinumab dermatitis drug in dermatological indications. The deal gives Leo a drug that has already released Phase IIb at a time when it is trying to expand its dermatology business. LEO Pharma has entered into a licensing agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma. According to a press release dated April 15, 2020, Leo Pharma has signed the exclusive global agreement with Oneness Biotech of Taiwan and Microbio Shanghai of China. Under the terms of the agreement, Leo Pharma will provide a down payment of $40 million and offer milestone payments of up to $US 530 million, in addition to tiered royalties. Oneness will lead the Phase IIa study of FB825 in patients with AD in the United States, and Microbio Shanghai will lead the Phase IIa study of allergic asthma in China. BALLERUP, the Danish leO (BUSINESS WIRE) Pharma A/S, a global leader in medical dermatology, today announced that it has signed an exclusive worldwide license agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China), which covers the development and commercialization of the new atopic dermatitis (AD) and asthma allergic candidate FB825.

Atopic dermatitis (eczema) is a disease that makes your skin red and itchy. This is common in children, but it can occur at any age.